sevelamer carbonate
sevelamer carbonate: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.
sevelamer carbonate evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could sevelamer carbonate → SNY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
Development Pipeline (2)
| Company | Phase |
|---|---|
| Sanofi (SNY) | Approved |
| Sanofi (SNY) | Approved |
Clinical Trials (1)
Randomized Placebo Controlled Double-blind Trial in CKD Patients Not on Dialysis to Evaluate the Effect of Sevelamer Carbonate in the Control of FGF-23 Serum Levels and Its Consequences in the Evolution of PTH, Calcitriol and Mineral Metabolism Parameters Levels
Primary endpoint: Measurement of the serum levels of C terminal segment of fibroblast growth factor 23 (FGF23) and evaluation of sevelamer carbonate effect on this levels in comparison with placebo
FDA Decisions1 records
Frequently asked questions
Who is developing sevelamer carbonate?
sevelamer carbonate is being developed by Sanofi.
How many clinical trials involve sevelamer carbonate?
BioSniper tracks 1 clinical trial involving sevelamer carbonate.
What is sevelamer carbonate's latest FDA decision?
The most recent tracked FDA decision for sevelamer carbonate is Approval for 1 INDICATIONS AND USAGE Sevelamer carbonate is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis. Sevelamer carbonate is a phosphate binder indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis. ( 1 ), dated October 19, 2007.